Taejoon Pharm Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1978)
Status: No NME R&D (1978)

Organization Overview

First Clinical Trial
2014
NCT02461719
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Taejoon Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (4)

cyclosporine (sandimmune) (3 trials)

iohexol (Omnipaque) (1 trial)

latanoprost (xalatan) (2 trials)

tafluprost (zioptan) (1 trial)

Drugs in Phase 3 Trials (3)

ctp0303 (1 trial)

deucravacitinib (Sotkyktu) (1 trial)

polyethylene glycol (1 trial)

Drugs in Phase 2 Trials (2)

diquafosol (1 trial)

tjo-083 (1 trial)

Drugs in Phase 1 Trials (1)

cto0101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 4)

Eye Diseases (Phase 4)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 3)

Hypertension (Phase 3)

Keratoconjunctivitis Sicca (Phase 4)

Ocular Hypertension (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 10